Alzamend Neuro amends bylaws to lower stockholder quorum to 35%, creates Series C Preferred Stock

Alzamend Neuro, Inc.

Board reduced quorum for stockholder meetings from majority of outstanding shares to 35%.
Filed Certificate of Designation for Series C Convertible Preferred Stock with Delaware.
Series C issuance part of previously disclosed exchange and purchase agreement with a sophisticated investor.
Exchange of 97.7511 shares of Series A for Series C; up to 500 additional Series C shares to be sold.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Alzamend Neuro, Inc.: Decreased stockholder meeting quorum requirement from majority to 35% of outstanding capital stock entitled to vote (effective 2025-02-28).

Change: bylaw amendment
Effective: 2025-02-28

Exact text from the filing

The only substantive change of the First Amendment from the Bylaws was to amend Article II, Section 2.6 of the Bylaws to decrease the quorum requirement for a meeting of stockholders from a majority of the outstanding capital stock of the Company entitled to vote, represented in person or by proxy, to 35% of the outstanding capital stock of the Company entitled to vote, represented in person or by proxy.

View on SEC.gov

13 governance changes filed in the last 30 days. Browse all governance changes →

Alzamend Neuro, Inc. filing history →

Source: SEC EDGAR

accession 0001214659-25-003727

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.